Roche's Avastin Rejected by National Institute for Clinical Excellence (NICE) for Use in Breast Cancer

Published: Apr 18, 2012

Roche Holding AG (ROG)’s Avastin doesn’t meet cost criteria for extending the lives of breast-cancer patients when combined with the chemotherapy drug capecitabine, and shouldn’t be used as a first-line treatment, the U.K. medical-spending regulator said.

An appraisal by the National Institute for Health and Clinical Excellence found it was unclear whether Avastin, also known as bevacizumab, extended overall survival and improved patients’ quality of life more than capecitabine alone, the agency said today in a statement.

Back to news